Comparison of Safety and Efficacy of Detaenial Sigmoid Neobladder and Ileal Neobladder
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Bladder cancer is a common malignant tumor of the urinary system, radical resection plus urinary diversion is the first choice of treatment for muscle invasive bladder cancer. Urinary diversion of surgical options related to patient' survival and quality of life. In 1988, Hautmann firstly reported an orthotopic urinary diversion method: Hautmann neobladder. As the urine can be controlled from the original urethra, the patient's quality of life has been greatly improved, so the new bladder surgery gradually accepted and welcomed by urologists and patients. However, in order to achieve low-pressure and large-volume storage capacity of the urine reservoir, the 40-70cm long interception of terminal ileum need to be detubularized. Only after split, folded, re-stitched and a series of treatment, the intestinal can be used. Such complicated procedures make so many urologists give it up. In addition, the interception of the long ileum may lead to reduced absorption of vitamin B12 which caused anemia, metabolic acidosis, intestinal dysfunction. Not only that, as time goes by, this kind of neobladder will be unlimited expansion and resulting in a serious increase in residual urine volume, hydronephrosis, or even the occurrence of neobladder spontaneous rupture. In 2000, professor Chunxiao Liu invented "detaenial sigmoid neobladder", this surgical method overset the traditional intestinal detubularization approach, which detached the serosal layer with smooth muscle from the bowel without split it. This kind of neobladder is easier to construct and have less impact on intestinal function. So far, it has been implemented for more than 600 cases in Zhujiang hospital, the age of patients range from 9 months (bladder rhabdomyosarcoma) to 84 years old. So far as now, no multicenter prospective clinical study on orthotopic urinary diversion has been performed worldwide, neither the head-to-head studies on detaenial sigmoid neobladder and ileal neobladder. Our project is going to perform a multicenter randomized controlled trial for these two neobladder methods and look forward to assess the safety and efficacy of these two procedures which provide an objective basis for the patients undergoing orthotopic urinary diversion in the future.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Rak pęcherza moczowego w różnych stadiach zaawansowania
- •Nawracający rak pęcherza
- •Inne wskazania do zabiegu pęcherza sztucznego zatwierdzone przez urologa
- •Wcześniejsze leczenie chemią w pęcherzu lub podane inną drogą
- •Dobrowolna zgoda na udział w badaniu
✗ Disqualifies
- •Zaburzenia funkcji nerek (wysokie kreatyniny w krwi)
- •Rak rozprzestrzenił się do cewki moczowej
- •Inne nowotwory złośliwe w ciągu ostatnich 5 lat
- •Przewlekłe zapalenie jelit lub jelita grubego
- •Inne powody uniemożliwiające zabieg sztucznego pęcherza
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 100 Years
- Last updated (source)
- October 9, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Zhujiang Hospital
Guangzhou, China
Trial contact
Abai Xu, doctor
Peng Xu, doctor
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/10/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.